Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Twelve analysts rate Disc Medicine (NASDAQ: IRON) an average of "Moderate Buy"—10 buys, 1 hold and 1 sell—with a 12‑month average price target of $104.80.
• Price targets have been trimmed recently (Stifel, Cantor Fitzgerald, Wedbush on Feb 17) while the stock trades around $68.32, well below the consensus target and its 1‑year high of $99.50; market cap is about $2.61B and the company shows a negative P/E.
• Operational and insider activity: Q4 EPS of −$1.62 beat estimates (−$1.69) but revenue was reported unfavorable, and insiders (including the CEO and COO) sold a total of 59,410 shares (~$3.84M) last quarter, leaving insiders with 3.64% ownership.

Shares of Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $104.80.

Several brokerages recently weighed in on IRON. Stifel Nicolaus reduced their target price on shares of Disc Medicine from $125.00 to $110.00 and set a "buy" rating on the stock in a report on Tuesday, February 17th. Cantor Fitzgerald reduced their target price on shares of Disc Medicine from $153.00 to $125.00 and set an "overweight" rating on the stock in a report on Tuesday, February 17th. Wedbush reduced their target price on shares of Disc Medicine from $110.00 to $88.00 and set an "outperform" rating on the stock in a report on Tuesday, February 17th. Raymond James Financial reaffirmed a "market perform" rating on shares of Disc Medicine in a report on Thursday, January 15th. Finally, Morgan Stanley set a $75.00 target price on shares of Disc Medicine in a report on Tuesday, February 17th.

Disc Medicine Stock Down 2.0%

Shares of IRON opened at $68.32 on Friday. The company's 50-day simple moving average is $64.16 and its 200-day simple moving average is $76.22. The company has a debt-to-equity ratio of 0.04, a quick ratio of 21.94 and a current ratio of 21.94. Disc Medicine has a 1 year low of $40.00 and a 1 year high of $99.50. The stock has a market capitalization of $2.61 billion, a PE ratio of -11.41 and a beta of 0.91.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, beating the consensus estimate of ($1.69) by $0.07. The firm had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. Analysts forecast that Disc Medicine will post -6.68 earnings per share for the current fiscal year.

Insider Transactions at Disc Medicine

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 3,231 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $203,100.66. Following the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at $3,414,806.64. This represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John D. Quisel sold 13,264 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $833,775.04. Following the completion of the transaction, the chief executive officer owned 226,064 shares in the company, valued at $14,210,383.04. This represents a 5.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 59,410 shares of company stock valued at $3,840,013 over the last quarter. Insiders own 3.64% of the company's stock.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds have recently added to or reduced their stakes in IRON. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Disc Medicine by 22.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company's stock valued at $756,000 after purchasing an additional 2,807 shares during the last quarter. Millennium Management LLC increased its stake in Disc Medicine by 1,277.1% in the first quarter. Millennium Management LLC now owns 108,499 shares of the company's stock valued at $5,386,000 after purchasing an additional 100,620 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Disc Medicine by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock valued at $4,793,000 after purchasing an additional 3,454 shares during the last quarter. Legal & General Group Plc increased its stake in Disc Medicine by 18.0% in the second quarter. Legal & General Group Plc now owns 24,097 shares of the company's stock valued at $1,276,000 after purchasing an additional 3,682 shares during the last quarter. Finally, Invesco Ltd. increased its stake in Disc Medicine by 21.6% in the second quarter. Invesco Ltd. now owns 16,817 shares of the company's stock valued at $891,000 after purchasing an additional 2,983 shares during the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.